Quick answer: There is no universal maximum number of months or years that everyone should remain on semaglutide. When it is effective, tolerated, medically appropriate and accessible, semaglutide may be used as long-term treatment for chronic weight management.

Reaching a goal weight does not automatically mean treatment should stop. Semaglutide can help maintain weight reduction, while discontinuation commonly allows appetite and weight-promoting biology to return.

Treatment should be reviewed periodically. Reasons to reconsider it include inadequate benefit, significant side effects, pregnancy, a serious complication, changing health needs, cost or inability to obtain the medication reliably.

Is semaglutide intended for short-term or long-term use?

FDA-approved Wegovy is indicated to reduce excess body weight and maintain weight reduction long term in qualifying patients, together with a reduced-calorie diet and increased physical activity.[1]

This is important: Wegovy is not labeled merely as a brief “kick-start” treatment.

Obesity is commonly a chronic, relapsing condition influenced by:

• Genetics
• Appetite-regulating hormones
• Energy expenditure
• Sleep
• Medications
• Environment
• Medical conditions
• Previous weight loss and regain

Semaglutide does not permanently remove these influences. Its effects on appetite and satiety generally continue only while the medication remains active.

How long was semaglutide studied in clinical trials?

Several major trials help explain why treatment may extend beyond a few months.

STEP 1: 68 weeks

In STEP 1, adults with overweight or obesity who did not have diabetes received once-weekly semaglutide 2.4 mg or placebo, plus lifestyle intervention, for 68 weeks.

Participants assigned to semaglutide lost an average of 14.9% of their starting weight, compared with 2.4% with placebo.[2]

Average weight continued declining for many months rather than reaching its full effect immediately.

STEP 5: 104 weeks

STEP 5 followed adults receiving semaglutide 2.4 mg or placebo for two years.

After 104 weeks, average weight change was:

• -15.2% with semaglutide
• -2.6% with placebo[3]

Average weight loss plateaued around week 60 and was largely maintained through the rest of the two-year trial while treatment continued.

This demonstrates that semaglutide can be used to maintain weight reduction—not only produce the initial loss.

SELECT: Several years of cardiovascular follow-up

SELECT included 17,604 adults with established cardiovascular disease and overweight or obesity who did not have diabetes.

Participants received semaglutide 2.4 mg or placebo for a mean treatment duration of approximately 33 months. Semaglutide reduced the relative risk of cardiovascular death, nonfatal heart attack or nonfatal stroke by 20% in this specific high-risk population.[4]

These findings do not establish one required treatment duration for everyone. They show that semaglutide has been studied beyond a brief weight-loss period.

Do you stop semaglutide after reaching your goal weight?

Not automatically.

Reaching a goal may signal a transition from active weight loss to maintenance. Continued treatment may help:

• Control appetite
• Reduce food cravings
• Maintain smaller portions
• Prevent or reduce regain
• Preserve improvements in weight-related health risks

Stopping simply because the scale reached a certain number can remove part of the system that helped produce that result.

A maintenance discussion should consider:

• How much weight was lost
• How long it has been stable
• Improvements in health conditions
• Current side effects
• Current dose
• Nutrition and physical activity
• Cost and coverage
• Patient preference
• Likelihood of regain
• Alternative maintenance options

The appropriate maintenance dose may not be identical for every patient. Dose changes should be directed by the prescriber.

Does semaglutide stop working after a certain time?

Semaglutide does not necessarily “wear out,” but weight loss normally slows.

As body weight decreases:

• A smaller body requires fewer calories.
• Resting energy expenditure may decline.
• Appetite-regulating biology may resist further loss.
• The same diet may no longer produce the original deficit.
• Early water-weight changes no longer contribute.

A plateau can be expected even when treatment is still helping control appetite and maintain prior loss.

Do not define failure solely because weight has stopped declining. Without continued treatment, weight might otherwise increase.

How do you know whether semaglutide is still helping?

A treatment review should consider more than the latest scale reading.

Possible benefits include:

• Percentage of starting weight lost
• Maintaining previous weight loss
• Reduced waist circumference
• Better appetite control
• Improved blood pressure
• Improved glucose or A1c
• Better lipid measurements
• Improved mobility
• Reduced symptoms from a weight-related condition
• Cardiovascular benefit in patients who meet the specific indication

The prescriber should balance these benefits against adverse effects, burden, cost and medical risk.

When should semaglutide benefit be reassessed?

There is no single universal reassessment date that applies to every formulation, dose and indication.

A meaningful assessment should occur after:

• Enough time has passed for dose escalation
• The patient has had adequate exposure to an appropriate therapeutic dose
• Administration and adherence have been verified
• Significant side effects have been addressed
• Lifestyle and medical factors have been reviewed

Earlier review is appropriate when:

• Weight is rapidly increasing
• The medication seems to have no effect
• Side effects prevent escalation
• Doses are repeatedly missed
• Supply interruptions are frequent
• The patient is unsure about the product or dose
• Cost threatens continuity
• A new medical condition develops

Do not judge the final response based only on the first month at an introductory dose.

Reasons a clinician might continue semaglutide

Continued treatment may be reasonable when:

• Weight reduction is clinically meaningful.
• Previous loss is being maintained.
• Appetite control remains improved.
• Weight-related health markers have improved.
• Side effects are manageable.
• No contraindication or serious complication has developed.
• The medication remains affordable and accessible.
• The patient prefers to continue after informed discussion.

The absence of continued weight loss does not necessarily eliminate maintenance benefit.

Reasons semaglutide may need to be stopped or changed

1. Serious adverse effects

Immediate discontinuation and medical evaluation may be necessary for suspected pancreatitis or a serious allergic reaction.

Other significant problems may require interruption, dose reduction or discontinuation, including:

• Repeated vomiting
• Severe dehydration
• Acute kidney injury related to volume loss
• Severe gastrointestinal intolerance
• Gallbladder complications
• Inability to maintain nutrition
• Another clinician-identified serious reaction

Do not attempt to manage severe symptoms merely by spacing doses farther apart.

2. Pregnancy

For weight reduction or cardiovascular risk reduction, current Wegovy labeling advises discontinuing treatment when pregnancy is recognized.[1]

Because semaglutide remains in the body for an extended period, the label advises stopping it at least two months before a planned pregnancy when used for these indications.[1]

Discuss pregnancy plans before attempting conception.

3. Inadequate benefit

If there is little meaningful benefit after adequate treatment at an appropriate dose, the clinician may reassess:

• Diagnosis and treatment goals
• Adherence
• Administration technique
• Nutrition
• Physical activity
• Sleep
• Weight-promoting medications
• Endocrine or other medical conditions
• Alternative treatment options

The decision should not be based solely on comparison with an unusually dramatic online transformation.

4. Intolerable side effects

Some patients cannot tolerate an effective dose despite slower escalation and supportive care.

The prescriber may consider:

• Delaying escalation
• Using a lower labeled maintenance dose when appropriate
• Changing formulation
• Switching treatment
• Discontinuing semaglutide

Do not continue escalating through unresolved vomiting, dehydration or significant nutritional decline.

5. A new contraindication or change in health

Treatment may need reconsideration after:

• A serious hypersensitivity reaction
• Pregnancy
• A new diagnosis affecting medication safety
• A severe gastrointestinal condition
• A major change in other medications
• Development of symptoms suggesting a serious complication

6. Cost, coverage or supply

A treatment that cannot be obtained consistently may be difficult to sustain.

Before the final dose, ask about:

• Insurance appeals
• Formulary alternatives
• Manufacturer programs when applicable
• Clinically appropriate alternatives
• A structured maintenance plan
• Safe restarting instructions if coverage returns

Do not stretch the medication by changing the interval or taking partial doses without instructions.

Do you need to taper semaglutide?

FDA labeling does not require a taper to prevent a classic medication-withdrawal syndrome.

Semaglutide does not produce the type of physical dependence associated with substances such as opioids, alcohol or benzodiazepines. Stopping does not generally cause a dangerous withdrawal syndrome simply because the dose was not tapered.

However, appetite may increase as the medication leaves the body, and weight regain can occur.

Some clinicians may use an individualized step-down strategy, but evidence has not established one universal taper schedule that reliably prevents regain. Do not improvise a taper by:

• Spacing injections unpredictably
• Splitting pens
• Taking partial doses
• Combining formulations
• Switching to a compounded product without appropriate evaluation

If semaglutide is being stopped for a serious adverse reaction or pregnancy, a gradual reduction may not be appropriate.

What happens after the last dose?

Semaglutide has a half-life of approximately one week and remains in the circulation for several weeks after the final dose.

Therefore:

• Appetite may not return immediately.
• Side effects may take time to resolve.
• Glucose effects may diminish gradually.
• Regain usually develops over months rather than overnight.

In the STEP 1 extension, participants who stopped semaglutide and lifestyle intervention regained approximately two-thirds of their previous weight loss during the following year.[5]

This does not mean everyone regains the same amount. It demonstrates that regain is common and that obesity often requires ongoing management.

Can lifestyle changes prevent regain after stopping?

Nutrition, activity, sleep and behavioral support remain important, but they may not fully replace the medication’s appetite effects.

A discontinuation plan may include:

• Regular weight monitoring
• Adequate dietary protein
• High-fiber foods as tolerated
• Resistance exercise
• Routine physical activity
• Consistent sleep
• Limiting calorie-dense beverages
• Behavioral or dietitian support
• Treatment of binge eating, depression or sleep apnea
• Discussion of another medication when appropriate

The plan should be established before appetite and weight increase substantially.

Should semaglutide be stopped before surgery?

Do not make this decision independently.

Semaglutide delays gastric emptying, and rare pulmonary-aspiration events have been reported during general anesthesia or deep sedation. Current labeling instructs patients to inform healthcare providers about planned surgery or procedures.[1]

The anesthesia plan may depend on:

• Whether treatment is in the escalation phase
• The formulation and dose
• Gastrointestinal symptoms
• Procedure type
• Type of anesthesia
• Individual aspiration risk
• Current professional guidance and facility policy

Tell the surgeon, proceduralist and anesthesia team well before the procedure.

What if treatment is interrupted?

Contact the prescriber before restarting after a significant interruption.

For Wegovy injection, current labeling states that after two or more consecutive missed doses, dosage escalation should be restarted at a lower dose to reduce gastrointestinal adverse reactions.[1]

Returning immediately to a previously tolerated high dose can cause substantial nausea, vomiting or dehydration because tolerance may have diminished.

Restart instructions differ by product and formulation.

Can you stay on semaglutide forever?

“Forever” cannot be promised because health status, treatment options, insurance and preferences can change.

A better question is:

Does the treatment continue to offer more benefit than risk for this patient?

If the answer remains yes, long-term treatment may be appropriate. If the answer changes, the plan should change.

Periodic follow-up should review:

• Weight and waist trend
• Blood pressure
• Glucose when applicable
• Side effects
• Nutrition
• Strength and muscle preservation
• Other medications
• Treatment goals
• Pregnancy plans
• Cost and access
• Whether the current dose remains appropriate

Frequently asked questions

Is six months long enough to use semaglutide?

It may not be enough time to capture the full response because dose escalation takes time and weight loss in trials continued for many months. Individual reassessment remains necessary.

Should I stop when I reach a normal BMI?

Not automatically. BMI is only one measure, and stopping may increase the risk of regain. Review benefits, risks and maintenance options with the prescriber.

Can I take semaglutide only until I lose 20 pounds?

A fixed-pound target does not determine whether stopping is medically appropriate. The likelihood of regain and long-term health goals should be discussed before treatment begins.

Does long-term use damage the metabolism?

Available evidence does not show that semaglutide permanently damages metabolism. Regain after stopping is better explained by loss of the medication’s effects and the biological tendency to regain weight.

Will I become addicted to semaglutide?

Semaglutide does not cause intoxication or a classic addiction syndrome. Long-term use may still be necessary because the condition being treated is chronic.

Can I lower the dose after reaching my goal?

A clinician may consider an appropriate labeled maintenance dose based on response and tolerability. Do not lower it or space injections without instructions.

What if insurance suddenly stops covering it?

Contact the prescriber before the remaining supply is exhausted. A planned transition is safer than unplanned interruptions or obtaining an unverified product.

Can I restart later?

Sometimes, but restarting may require lower-dose escalation. Do not return directly to a previous maintenance dose after a prolonged interruption.

Bottom line

There is no universal deadline for stopping semaglutide.

Long-term treatment may be reasonable when the medication:

• Produces meaningful benefit
• Helps maintain weight reduction
• Remains tolerable
• Is medically appropriate
• Is accessible and sustainable

Treatment should be reassessed when benefit is inadequate, side effects are significant, pregnancy occurs or is planned, a serious complication develops, or access becomes unreliable.

Reaching a goal weight is often the beginning of maintenance—not proof that treatment is finished. Discuss duration and the eventual stopping plan with the prescriber before making changes.

---

Medical review: Mark Aquino, MSN, APRN, FNP-C, board-certified family nurse practitioner.

Medical disclaimer: This article provides general educational information and is not individualized medical advice. Decisions about continuing, changing or stopping semaglutide must be made with a qualified healthcare professional using the instructions for the exact product and indication.

References

1. Novo Nordisk Inc. Wegovy (semaglutide) injection and tablets: US prescribing information. Revised June 2026.
2. Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989-1002. doi:10.1056/NEJMoa2032183.
3. Garvey WT, Batterham RL, Bhatta M, et al. Two-year effects of semaglutide in adults with overweight or obesity: the STEP 5 trial. Nat Med. 2022;28(10):2083-2091. doi:10.1038/s41591-022-02026-4.
4. Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221-2232. doi:10.1056/NEJMoa2307563.
5. Wilding JPH, Batterham RL, Davies M, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553-1564. doi:10.1111/dom.14725.